Jupiter Bioscience Peer Comparison

NSE: JUPITER | BSE: 524826

₹3.97

₹-0.12 (-2.93%)

As on 15-Jan-2013IST

Market cap

₹25 Cr

Revenue (TTM)

₹168 Cr

P/E Ratio

P/B Ratio

Div. Yield

25.2 %

Edit

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	25	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	168	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-2.81	414.00	288.22	-371.81	387.35
Net Margin (%)	-1.67	11.23	14.79	-3.93	26.01
RoE (%)	-0.34	8.38	29.77	-3.85	25.18
Price to Earnings	--	78.49	103.71	--	69.57
Price-To-Book	0.03	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	331.26	3,751.24	21.05	--	27.82
Total Income	331.43	3,903.86	21.47	--	28.52
Total Expenditure	185.04	2,835.28	15.03	--	25.24
EBITDA	146.23	915.96	6.02	--	2.57
Depreciation	58.76	116.62	1.79	--	0.73
EBIT	87.46	799.34	4.23	--	1.84
Interest	29.35	267.10	1.27	--	0.63
Other Income	0.17	152.62	0.42	--	0.70
Exceptional Items	--	-580.51	--	--	--
Profit before Tax	58.28	104.35	3.38	--	1.91
Provision for Tax	6.92	8.65	1.00	--	0.66
Profit after Tax	51.36	95.70	2.38	--	1.26

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	853.59	943.10	34.96	--	4.76
Minority Interest	--	--	--	--	--
Non-Current Liabilities	475.30	2,943.95	6.74	--	7.05
Current Liabilities	34.89	1,919.01	14.88	--	8.28
Total Liabilities	1,363.78	5,880.91	56.58	--	20.22

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	1,072.98	3,903.85	45.59	--	6.10
Current Assets	208.52	1,902.21	11.00	--	13.99
Total Assets	1,363.78	5,880.91	56.58	--	20.22
Total Debt*	454.53	3,851.66	14.89	--	7.18
Net Current Assets	173.63	-16.80	-3.88	--	5.71
Contingent Liabilities	--	503.13	0.62	--	--

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	117.54	641.81	5.64	--	--
Cash Flow from Investing Activities	-514.40	-276.61	-4.90	--	--
Cash from Financing Activities	394.71	-372.99	-1.13	--	--
Net Cash Inflow / Outflow	-2.15	-7.79	-0.40	--	--

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	8.77	7.83	9.33	--	25.13
ROE (%)	10.00	95.20	14.88	--	30.45
ROA (%)	4.59	1.67	4.20	--	7.45
EBIT Margin (%)	44.19	28.49	30.59	--	11.78
Net Margin (%)	15.50	2.45	11.06	--	4.40
Cash Profit Margin (%)	33.24	5.65	19.78	--	6.67

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	42.45	-16.67	0.00	--	43.96
EBIT Growth (%)	22.43	33.59	--	--	35.96
Net Profit Growth (%)	20.92	109.55	0.00	--	32.56
EPS Growth (%)	-65.84	109.05	0.00	--	32.56
Book Value Growth (%)	141.34	6,150.47	0.00	--	36.01

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	2.49	36.13	0.00	--	0.00
Price / Book Value	0.18	17.93	0.00	--	0.00
Dividend Yield (%)	5.04	0.00	--	--	--
EV/EBITDA	3.95	7.17	5.48	--	2.62
Market Cap (₹ Cr)	128.10	3,548.59	0.00	--	0.00

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.63	4.08	0.43	--	1.51
Short term debt to equity ratio	--	0.41	0.12	--	--
Current Ratio	5.98	0.99	0.74	--	1.69
Quick Ratio	3.74	0.62	0.74	--	1.32
Interest Coverage	2.99	1.39	3.66	--	4.02

	Jupiter Bioscience	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	24.77	16.13	38.72	--	29.17
Asset Turnover	0.30	0.65	0.37	--	1.77
Receivable days	77.35	57.31	141.31	--	88.98
Inventory Days	80.61	71.89	0.00	--	27.75
Payable days	28.11	104.96	535.25	--	122.14
Cash Conversion Cycle	129.85	24.24	-393.94	--	-5.40

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.